|The CD357 n/a (Catalog #MBS666414) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The anti-human CD357(GITR)-FITC reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s CD357 can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS), ELISA (EIA).
1:50 (or use 1.6 ul of concentrated reagent per 5 x 105-cell test). Researchers should empirically determine the suitability of the CD357 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the anti-human CD357(GITR)-FITC with the following immunoassay(s):
Information: Glucocorticoid induced Tumor Necrosis Factor receptor family related gene (CD357, GITR, AITR) is a type 1 228 amino acid transmembrane protein that has been designated TNFRSF18. GITR is expressed mainly by CD4+ CD25+ T lymphocytes. Its engagement by antibodies or its ligand (GITRL) induces a costimulatory signal which can break T cell suppression (2). GITR has been implicated as a regulatory mechanism in anti-parasitic immune resposes (4), and is involved with Macrophages activation in atherosclerotic plaque formation (3).
Clone ANC7D6-1E7 binds to human CD357 in EIA and on stimulated cell surface in FACS. Pre incubation of the receptor with an excess of this mAb will block binding of recombinant GITR Ligand.
Performance: Ficoll prepared human peripheral blood mononuclear cells (PBMC) were stimulated 5 days in culture with PHA. Five x 105 cells per tube were washed and pre incubated 5 minutes with 20 ul of 250 ug/ml human IgG (to block non specific binding) after which they were incubated 45 minutes on ice with 80 ul of anti-GITR/FITC at a 1:50 dilution factor (10ug/ml). Cells were washed three times, fixed and analyzed by FACS. Cells stained positive with a mean shift of 1.03 log10 fluorescent units when compared to a Mouse IgM/FITC negative control at a similar concentration. Binding was blocked when cells were pre incubated with a 10-fold excess of unlabeled anti-GITR mAb. Conjugation: FITC
Production: Antibody from (low FBS containing) tissue culture supernatant was purified by size exclusion chromatographand reacted with FITC. Unconjugated FITC was removed from conjugate using a desalting column. Antibody conjugate is at 0.5 mg/ml with a Fluorescein/IgM molar ratio of 35.
Buffer: 50 mM Sodium Phosphate pH 7.5, 500 mM Potassium Chloride, 150mM NaCl, 5% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative).
Immunogen: Recombinant human GITR, PHA stimulated human PBL. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD357 are readily searchable from our website. Different antibodies against the same target such as CD357 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.